Gyre Therapeutics (GYRE) Current Leases (2019 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Current Leases of $751000.0 for Q1 2026, down 6.71% year-over-year from $805000.0 in Q1 2025, and up 18.08% quarter-over-quarter from $636000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Current Leases (2019 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Current Leases for 8 consecutive years, with $751000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 6.71% year-over-year to $751000.0; the TTM figure through Mar 2026 stood at $751000.0 (down 6.71% YoY), while the FY2025 annual figure was $636000.0, down 10.8% from the prior year.
- Current Leases grew to $751000.0 in Q1 2026 per GYRE's latest filing, from $636000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.9 million in Q1 2022 and bottomed at $100000.0 in Q1 2024.
- Historically, Current Leases has averaged $715214.3 across 5 years, with a median of $647500.0 in 2024.
- Annual changes were most pronounced in 2022 — Current Leases plunged 79.34% — and 2025, when it jumped 705.0%.
- Gyre Therapeutics' Current Leases stood at $492000.0 in 2022, then tumbled by 57.32% to $210000.0 in 2023, then soared by 239.52% to $713000.0 in 2024, then declined by 10.8% to $636000.0 in 2025, then gained by 18.08% to $751000.0 in 2026.
- Business Quant data shows GYRE's Current Leases at $751000.0 in Q1 2026, $636000.0 in Q4 2025, and $626000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 751,000.00 |
| Dec 31, 2025 | 636,000.00 |
| Sep 30, 2025 | 626,000.00 |
| Jun 30, 2025 | 622,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 713,000.00 |
| Sep 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 659,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 492,000.00 |
| Sep 30, 2022 | 381,000.00 |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 678,000.00 |
| Dec 31, 2020 | 663,000.00 |